X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (275) 275
Patent (18) 18
Conference Proceeding (6) 6
Publication (3) 3
Book Review (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (115) 115
humans (98) 98
female (85) 85
middle aged (77) 77
male (67) 67
aged (64) 64
adult (56) 56
oncology (45) 45
original (30) 30
cancer (28) 28
treatment outcome (28) 28
original article (27) 27
chemotherapy (24) 24
retrospective studies (20) 20
antineoplastic combined chemotherapy protocols - therapeutic use (19) 19
breast cancer (19) 19
analysis (18) 18
prognosis (18) 18
aged, 80 and over (17) 17
care and treatment (17) 17
prospective studies (17) 17
risk factors (17) 17
animals (16) 16
breast neoplasms - pathology (16) 16
disease-free survival (16) 16
medicine & public health (16) 16
research (16) 16
surgery (16) 16
breast neoplasms - drug therapy (15) 15
republic of korea (15) 15
young adult (15) 15
antineoplastic combined chemotherapy protocols - adverse effects (14) 14
survival (14) 14
apoptosis (13) 13
therapy (13) 13
time factors (13) 13
clinical neurology (12) 12
mice (12) 12
abridged index medicus (11) 11
follow-up studies (11) 11
medicine, general & internal (11) 11
stroke (11) 11
gastroenterology & hepatology (10) 10
metaanalysis (10) 10
metastasis (10) 10
patients (10) 10
survival rate (10) 10
carcinoma (9) 9
correction of typographical errors (9) 9
i.e. mechanisms printing otherwise than from a forme (9) 9
lining machines (9) 9
lung neoplasms - drug therapy (9) 9
paclitaxel (9) 9
paclitaxel - administration & dosage (9) 9
performing operations (9) 9
pharmacology & pharmacy (9) 9
printing (9) 9
risk (9) 9
selective printing mechanisms (9) 9
stamps (9) 9
survival analysis (9) 9
transporting (9) 9
typewriters (9) 9
breast neoplasms - mortality (8) 8
disease (8) 8
epidemiology (8) 8
management (8) 8
medical research (8) 8
mortality (8) 8
neoplasm staging (8) 8
neurosciences (8) 8
outcomes (8) 8
proportional hazards models (8) 8
recurrence (8) 8
rehabilitation (8) 8
safety (8) 8
trastuzumab (8) 8
trial (8) 8
tumors (8) 8
antineoplastic agents - therapeutic use (7) 7
dose-response relationship, drug (7) 7
drug administration schedule (7) 7
drug therapy (7) 7
epidermal growth factor (7) 7
hematology, oncology and palliative medicine (7) 7
in-vitro (7) 7
inflammation (7) 7
kaplan-meier estimate (7) 7
medical colleges (7) 7
multivariate analysis (7) 7
necrosis (7) 7
neoplasm metastasis (7) 7
pain (7) 7
quality of life (7) 7
radiotherapy (7) 7
rats (7) 7
republic of korea - epidemiology (7) 7
adolescent (6) 6
biomarkers, tumor - analysis (6) 6
breast neoplasms - metabolism (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9816, pp. 633 - 640
Summary Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and... 
Internal Medicine | ADJUVANT CHEMOTHERAPY | APOPTOSIS | CELLS | WOMEN | MEDICINE, GENERAL & INTERNAL | GW572016 | ERBB2 | INHIBITOR | PLUS | Breast Neoplasms - surgery | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Liver - drug effects | Adult | Female | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Paclitaxel - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Liver - metabolism | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Neoadjuvant Therapy - methods | Quinazolines - adverse effects | Aged | Infusions, Intravenous | Receptor, ErbB-2 - analysis | Trastuzumab | Drug therapy | Breast cancer | Genetic aspects | Medical research | Ligands | Cytotoxicity | Mammography | Kinases | Cancer therapies | Index Medicus | Abridged Index Medicus | pathology | Liver | methods | Antibodies | Oral | Quinazolines | Breast Neoplasms | Tumor Markers | administration & dosage | Surgery | Paclitaxel | Neoadjuvant Therapy | Adjuvant | Monoclonal | chemistry | Administration | drug therapy | chemically induced | Intravenous | Infusions | Humanized | Antineoplastic Combined Chemotherapy Protocols | Diarrhea | drug effects | Biological | analysis | Kirurgi | antagonists & inhibitors | Chemotherapy | Receptor | adverse effects | metabolism | Cancer and Oncology | therapeutic use | Cancer och onkologi | erbB-2
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2010, Volume 28, Issue 20, pp. 3239 - 3247
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1700 - 1710
Summary Background Patients with advanced HER2-positive breast cancer frequently develop CNS metastases. The metastases that progress after brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | CAPECITABINE | BIBW 2992 | EFFICACY | ONCOLOGY | MUTATIONS | ERBB FAMILY BLOCKER | United States | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Vinblastine - therapeutic use | Brain Neoplasms - secondary | Breast Neoplasms - chemistry | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Adult | Female | Receptor, ErbB-2 - antagonists & inhibitors | Brain Neoplasms - mortality | Antineoplastic Agents, Phytogenic - therapeutic use | Biomarkers, Tumor - antagonists & inhibitors | Republic of Korea | Antineoplastic Agents, Phytogenic - adverse effects | Brain Neoplasms - chemistry | Trastuzumab - therapeutic use | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Disease Progression | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Quinazolines - adverse effects | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Care and treatment | Breast cancer | Product development | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1360 - 1372
Journal Article
European Journal of Cancer, ISSN 0959-8049, 09/2017, Volume 82, pp. 103 - 114
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 385 - 393
Paclitaxel plus gemcitabine (PG) combination chemotherapy is a preferred chemotherapeutic regimen for patients with metastatic breast cancer (MBC). Eribulin... 
Metastatic breast cancer | Eribulin | Chemotherapy | Gemcitabine | Paclitaxel | SURVIVAL | CRITERIA | HALICHONDRIN-B | SOLID TUMORS | VIVO ANTICANCER ACTIVITIES | STATISTICS | MESYLATE | IN-VITRO | THERAPY | ONCOLOGY | GROWTH | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Furans - adverse effects | Young Adult | Breast Neoplasms - enzymology | Neoplasm Metastasis | Time Factors | Adult | Deoxycytidine - adverse effects | Female | Paclitaxel - administration & dosage | Ketones - adverse effects | Republic of Korea | Biomarkers, Tumor - analysis | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Ketones - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Furans - administration & dosage | Antimitotic agents | Care and treatment | Analysis | Breast cancer | Metastasis | Antineoplastic agents | Cancer | Toxicity | Clinical trials | Taxane | Patients | Survival | ErbB-2 protein | Subgroups | Metastases | Neurotoxicity | Dynamic tests | Randomization | Epidermal growth factor | Anthracycline | Neutropenia | Index Medicus
Journal Article
Journal of Clinical Pathology, ISSN 0021-9746, 05/2012, Volume 65, Issue 5, pp. 441 - 446
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 03/2014, Volume 120, Issue 5, pp. 642 - 651
Patient‐reported outcomes from the phase 3 EMILIA study showed trastuzumab emtansine (T‐DM1) to have a more favorable effect on patient‐reported health... 
breast cancer | HER2‐positive | quality of life | antibody–drug conjugate | ado‐trastuzumab emtansine | T‐DM1 | ado-trastuzumab emtansine | T-DM1 | antibody-drug conjugate | HER2-positive | Q-TWIST | INSTRUMENT | ONCOLOGY | FUNCTIONAL ASSESSMENT | QUALITY-OF-LIFE | MINIMALLY IMPORTANT DIFFERENCES | COMBINATION | BINOMIAL CONFIDENCE-INTERVALS | Medication Adherence - statistics & numerical data | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Diarrhea - chemically induced | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Time Factors | Adult | Female | Quinazolines - administration & dosage | Surveys and Questionnaires | Drug Administration Schedule | Fluorouracil - analogs & derivatives | Biomarkers, Tumor - analysis | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Self Report | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maytansine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quality of Life | Aged | Receptor, ErbB-2 - analysis | Health Status | Deoxycytidine - analogs & derivatives | Trastuzumab | Index Medicus | Abridged Index Medicus
Journal Article